Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: A randomized control trial

Regulatory Toxicology and Pharmacology

Volumn 63, Issue 2, 2012, Pages 313-320

  Jones, Mitchell L ^a,b   Martoni, Christopher J ^b   Di Pietro, E ^a,b   Simon, Ryan R ^c   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c Intertek Cantox   (Canada)

Author keywords

Adverse events; Cholesterol; Lactobacillus reuteri; Probiotic; Safety; Supplement; Toxicology

Indexed keywords

CARDIOVIVA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL STRAIN; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ERYTHROCYTE COUNT; EVENING DOSAGE; FEMALE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; INCREASED APPETITE; LACTOBACILLUS REUTERI; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OROPHARYNX PAIN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SHOULDER PAIN; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA BLOOD LEVEL; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; AGED; CAPSULES; CHOLESTEROL, LDL; CONSUMER PRODUCT SAFETY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LACTOBACILLUS REUTERI; MALE; MIDDLE AGED; PROBIOTICS; TREATMENT OUTCOME; YOUNG ADULT;

LACTOBACILLUS REUTERI;

EID: 84861407924     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.04.003     Document Type: Article

References (29)

1. Begley M., Hill C., Gahan C.G.M. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 2006, 72:1729-1738.
2. Branton W.B., Jones M.L., Tomaro-Duchesneau C., Martoni C.J., Prakash S. In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int. J. Probiotics Prebiotics 2011, 6:1-12.
3. Burton J.P., Cowley S., Simon R.R., McKinney J., Wescombe P.A., Tagg J.R. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem. Toxicol. 2011, 49:2356-2364.
4. Coccorullo P., Strisciuglio C., Martinelli M., Miele E., Greco L., Staiano A. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J. Pediatr. 2010, 157:598-602.
5. Connolly E., Abrahamsson T., Bjorksten B. Safety of d(-)-lactic acid producing bacteria in the human infant. J. Pediatr. Gastroenterol. Nutr. 2005, 41:489-492.
6. EFSA Panel on Biological Hazards Scientific Opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed. EFSA J. 2009, 7:1431. (2009 update).
7. EFSA Scientific Committee Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. EFSA J. 2007, 587:1-16.
8. FAO and WHO, 2002. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ont. Canada.
9. Ford E.S., Li C., Pearson W.S., Zhao G., Mokdad A.H. Trends in hypercholesterolemia, treatment and control among United States adults. Int. J. Cardiol. 2010, 140:226-235.
10. Gibson G.R., Brummer R.J., Isolauri E., Lochs H., Morelli L., Ockhuizen T., Rowland I.R., Schrezenmeir J., Stanton C., Verbeke K. The design of probiotic studies to substantiate health claims. Gut Microbes 2011, 2:299-305.
11. Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.H., Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol. Ther. 2007, 26:475-486.
12. Jones M.L., Martoni C.J., Parent M., Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br. J. Nutr. 2011, 1-9.
13. Lee D.Y., Seo Y.S., Rayamajhi N., Kang M.L., Lee S.I., Yoo H.S. Isolation, characterization, and evaluation of wild isolates of Lactobacillus reuteri from pig feces. J. Microbiol. 2009, 47:663-672.
14. Marteau P., Cuillerier E., Meance S., Gerhardt M.F., Myara A., Bouvier M., Bouley C., Tondu F., Bommelaer G., Grimaud J.C. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol. Ther. 2002, 16:587-593.
15. Marteau P.R. Probiotics in clinical conditions. Clin. Rev. Allergy Immunol. 2002, 22:255-273.
16. Metchnikoff E. The Prolongation of Life 1907, Heinemann Publishers, London.
17. Molin G., Andersson R., Ahrne S., Lonner C., Marklinder I., Johansson M.L., Jeppsson B., Bengmark S. Effect of fermented oatmeal soup on the cholesterol level and the Lactobacillus colonization of rat intestinal mucosa. Antonie Van Leeuwenhoek 1992, 61:167-173.
18. Naito S., Hayashidani H., Kaneko K., Ogawa M., Benno Y. Development of intestinal lactobacilli in normal piglets. J. Appl. Bacteriol. 1995, 79:230-236.
19. NCEP Expert Panel Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
20. Rosander A., Connolly E., Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 2008, 74:6032-6040.
21. Taranto M.P., Vera J.L., Hugenholtz J., de Valdez G.F., Sesma F. Lactobacillus reuteri CRL1098 produces cobalamin. J. Bacteriol. 2003, 185:5643-5647.
22. US FDA, 2008. GRAS Notice - Substance. Lactobacillus reuteri strain DSM, 17938.
23. Valderas J.M., Kotzeva A., Espallargues M., Guyatt G., Ferrans C.E., Halyard M.Y., Revicki D.A., Symonds T., Parada A., Alonso J. The impact of measuring patient-reported outcomes in clinical practice. a systematic review of the literature. Qual. Life Res. 2008, 17:179-193.
24. Vos P., Hogers R., Bleeker M., Reijans M., van de L.T., Hornes M., Frijters A., Pot J., Peleman J., Kuiper M. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Res. 1995, 23:4407-4414.
25. Weizman Z., Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J. Am. Coll. Nutr. 2006, 25:415-419.
26. WHO and FAO, 2001 Joint FAO/WHO Expert Consultation: Safety assessment of foods derived from genetically modified microorganisms. In: WHO and FAO (Eds.), WHO/SDE/PHE/FOS/01.3 Ed., pp. 1-28.
27. Wind R.D., Tolboom H., Klare I., Huys G., Knol J. Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers. Br. J. Nutr. 2010, 104:1806-1816.
28. Wolf B.W., Garleb K.A., Ataya D.G., Casas I.A. Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Microbial. Ecol. Health Dis. 1995, 8:41-50.
29. Wolf B.W., Wheeler K.B., Ataya D.G., Garleb K.A. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem. Toxicol. 1998, 36:1085-1094.